Tyra Biosciences, Inc. (TYRA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-01

Tyra Biosciences, Inc. (TYRA) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-01. 2 Form 8-K material event filings were reported by TYRA in the last 90 days. 3 Form 144 notices of proposed sale were filed for TYRA stock. InsiderAlpha tracks every TYRA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Tyra Biosciences, Inc. (TYRA)

SEC CIK	0001863127

90-Day SEC Filing Activity

Form 4 filings (90d)	13
Form 8-K filings (90d)	2
Form 144 notices (90d)	3
Latest Form 4 filing	2026-06-01

Recent TYRA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-05	Fuhrman Alan	Chief Financial Officer	A — Grant or award	20.0K	$0.00	—	SEC
2026-05-05	Harris Todd	President and CEO	A — Grant or award	79.0K	$0.00	—	SEC
2026-05-05	Warner Douglas J	Chief Medical Officer	A — Grant or award	25.0K	$0.00	—	SEC
2026-05-05	Rueb Yuliya	Vice President, Finance (PAO)	A — Grant or award	8.3K	$0.00	—	SEC
2026-05-05	Ashar Bhavesh	Chief Operating Officer	A — Grant or award	15.0K	$0.00	—	SEC
2026-03-26	KAPLAN GILLA	Insider	D — Derivative transaction	53.2K	$37.75	$2.01M	SEC
2026-03-26	KAPLAN GILLA	Insider	M — Option exercise	53.2K	$2.25	$120K	SEC
2026-03-25	KAPLAN GILLA	Insider	S — Open-market sale	14.3K	$36.97	$529K	SEC
2026-03-25	KAPLAN GILLA	Insider	M — Option exercise	14.3K	$2.25	$32K	SEC
2026-03-13	Harris Todd	President and CEO	A — Grant or award	1.5K	$9.13	$13K	SEC
2026-03-13	Fuhrman Alan	Chief Financial Officer	A — Grant or award	1.4K	$9.13	$13K	SEC
2026-02-12	Bensen Daniel	Chief Discovery Officer	S — Open-market sale [10b5-1]	5.9K	$33.37	$196K	SEC
2026-02-12	Bensen Daniel	Chief Discovery Officer	S — Open-market sale [10b5-1]	2.1K	$31.50	$67K	SEC
2026-01-12	Bensen Daniel	Chief Discovery Officer	S — Open-market sale [10b5-1]	7.0K	$28.44	$199K	SEC
2026-01-12	Bensen Daniel	Chief Discovery Officer	S — Open-market sale [10b5-1]	1.0K	$29.08	$30K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Tyra Biosciences, Inc. (TYRA). Updated in real time as new filings are submitted to the SEC.

Most-Active TYRA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Warner Douglas J	2	—
Fuhrman Alan	2	—
Ashar Bhavesh	2	—
Harris Todd	2	—
Rueb Yuliya	2	—

Recent TYRA Form 8-K Material Events

2026-06-02 — Item 5.07 [SEC]
2026-05-13 — Item 2.02, 9.01 [SEC]
2026-04-17 — Item 5.02 · Leadership · positive [SEC]
Tyra Biosciences appointed Habib J. Dable to its Board of Directors as a Class II director on April 16, 2026. Dable is an experienced pharmaceutical executive with significant industry credentials, including prior CEO roles at Acceleron Pharma and senior positions at Bayer, bring
2026-04-02 — Item 5.02 · Leadership · neutral [SEC]
Tyra Biosciences designated Julia Rueb, Vice President of Finance, as the Company's principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman in that role. Fuhrman remains as principal financial officer. This is an internal accounting function reassignment
2026-03-04 — Item 8.01 · Financing · neutral [SEC]
Tyra Biosciences agreed to issue 4 million shares of common stock at $31.50 per share to a large investment management firm under its at-the-market offering program, generating $126.0 million in gross proceeds. This is a standard equity capital raise executed through an existing

Recent TYRA Form 144 Notices of Proposed Sale

2026-06-26 — — [SEC]
2026-06-01 — — [SEC]
2026-05-12 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-06-01 — RA CAPITAL MANAGEMENT, L.P. (Insider)
2026-06-01 — Verjee Rehan (Insider)
2026-06-01 — Moran Susan (Insider)
2026-06-01 — Simson Jake (Insider)
2026-06-01 — Gulfo Adele M. (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in TYRA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

TYRA Insider Trading — FAQ

What is the latest insider trade for TYRA?: Tyra Biosciences, Inc. (TYRA) had 13 insider filings in the last 90 days, with the most recent on 2026-06-01. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying TYRA stock?: 0 insider purchases of TYRA were filed in the last 90 days.
How many insiders are selling TYRA stock?: 0 insider sales of TYRA were filed in the last 90 days.
Where can I see TYRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every TYRA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live TYRA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.